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CLINICAL REPORT
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aortic disease caused by pathogenic variants in the SMAD3 gene
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Abstract
Background: Predominant cardiovascular manifestations in the spectrum of Heri-
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table Thoracic Aortic Disease include by default aortic root aneurysms- and dis-

Correspondence
Julie De Backer, Ghent University
Hospital, Ghent, Belgium.
Email: julie.debacker@ugent.be

acterized by heart failure and/or malignant arrhythmias has been reported in
humans and in animal models harboring pathogenic variants in the Fibrillin1

sections, which may be associated with aortic valve disease. Mitral- and tricuspid
valve prolapse are other commonly recognized features. Myocardial disease, char-

gene.
Methods: Description of clinical history of three cases from one family in Ghent
(Belgium) and one family in St. Louis (US).
Results: We report on three cases from two families presenting end-stage heart
failure (in two) and lethal arrhythmias associated with moderate left ventricular
dilatation (in one). All three cases harbor a pathogenic variant in the SMAD3
gene, known to cause aneurysm osteoarthritis syndrome, Loeys-Dietz syndrome
type 3 or isolated Heritable Thoracic Aortic Disease.
Conclusions: These unusual presentations warrant awareness for myocardial disease in patients harboring pathogenic variants in genes causing Heritable Thoracic
Aortic Disease and indicate the need for prospective studies in larger cohorts.
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| INTRODUCTION

In recent years, both the genetic and clinical spectrum of
Heritable Thoracic Aortic Disease (H-TAD) has expanded
substantially. H-TAD comprises a heterogeneous group of
disorders with as a common denominator aortic aneurysm
or dissection on one or several levels of the aorta (Pyeritz,
2014).
Currently, known causal genes that have been identified
in H-TAD are commonly grouped into those affecting structure (i.e., genes encoding extracellular matrix (ECM)

components (FBN1(*134797), COL3A1 (*120180), MFAP5
(*601103), ELN (*130160), EFEMP2 (*604633)) and those
that affect the ability to modify structure in response to
changes in mechanical load imposed on the aortic wall. The
latter group can be divided into genes encoding various proteins involved in TGFb signaling (TGFBR15*190181),
TGFBR2 (*190182), TGFB2 (*190220), TGFB3 (*190230),
SMAD3 (*603109) and genes encoding proteins involved in
vascular smooth muscle cell contractility (ACTA2 (*102620),
MYH11 (*160745), MYLK (*600922), PRKG1 (*176894),
FLNA (*300017)).
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From a clinical cardiovascular perspective, the spectrum
broadened as well with attention also being paid to extraaortic cardiovascular manifestations. There has been growing evidence of intrinsic myocardial dysfunction in patients
with Marfan syndrome (MFS) caused by pathogenic variants in the FBN1 gene (Alpendurada et al., 2010; de
Backer et al., 2006; Kiotsekoglou et al., 2008; Loeper
et al., 2016; Rybczynski et al., 2007). Clinically overt heart
failure, even necessitating cardiac transplantation has been
reported in some cases and small series (Audenaert, de
Pauw, Francßois, & De Backer, 2015; Kesler et al., 1994;
Knosalla et al., 2007) but the majority of patients will present subclinical forms of myocardial dysfunction, the clinical impact of which is not entirely understood yet. It
cannot be excluded that myocardial involvement conveys
an increased risk for arrhythmias. Indeed, there are several
reports of an increased risk of ventricular arrhythmia and
SCD, related or not related to underlying myocardial dysfunction (Chen, Fagan, Nouri, & Donahoe, 1985; Hoffmann et al., 2012; Schaeffer et al., 2015; Yetman,
Bornemeier, & McCrindle, 2003). A correlation between
the risk for ventricular arrhythmias and ejection fraction
and NTpro-BNP levels has been documented in several
studies of these studies. Notably, heart failure and sudden
cardiac death in MFS has also been reported as a major
cause of death in earlier series and surgical reports (Gott
et al., 1999; Murdoch, Walker, Halpern, Kuzma, & McKusick, 1972).
One small study investigated the genotype in relation to
left ventricular (LV) function and noticed that LV dilatation
in MFS patients is more often seen in patients with a nonmissense FBN1 pathogenic variant and in those patients
without an FBN1 pathogenic variant (Aalberts et al., 2014).
Whether this latter group included patients harboring variants in other H-TAD genes is not known.
More recently, the observation of myocardial dysfunction was also confirmed in various mouse models for MFS
(Campens et al., 2015; Cook et al., 2014; Rouf et al.,
2017; Tae, Petrashevskaya, Marshall, Krawczyk, & Talan,
2016). The exact mechanism of these findings is largely
unexplained. Animal experimental studies may indicate a
perturbation in TGFb signaling or a malfunction in
mechanobiology, especially in mechanical sensing (Cook
et al., 2014). The importance of the TGFb pathway in the
aortic pathology of various HTAD entities has already been
demonstrated. Whether patients with pathogenic variants in
these genes also have an increased risk of developing cardiomyopathy or arrhythmias is less clear.
SMAD3 pathogenic variants can give rise to a form of
H-TAD, also characterized by osteoarthritis, hence the designation Aneurysm Osteoarthritis Syndrome (van de Laar
et al., 2011). Some patients with SMAD3 pathogenic variants exhibit typical characteristics of Loeys-Dietz syndrome
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(LDS), from which the term LDS type 3 is sometimes used
while others present very little outward syndromic features
and the term “Familial or Heritable Thoracic Aortic Disease” may be more appropriate (Regalado et al., 2011).
In a first published retrospective series on the clinical
cardiovascular characteristics of Aneurysm Osteoarthritis
patients, left ventricular hypertrophy was established in
19% of a cohort of 44 patients (van der Linde et al., 2012).
Patients also are reported to have a higher BNP values and
an increased PVC burden (van der Linde et al., 2012). Of
the 15 registered deaths in this series, six were due to aortic dissection, two from heart failure and three related to
sudden cardiac death.
Herein, we report two families (three cases) with a
pathogenic SMAD3 variant displaying severe heart failure
(two cases) and sudden cardiac death (one case), indicating
a possible relationship between SMAD3 pathogenic variants
and these manifestations to heighten awareness of this
association and to further evaluate in larger series.

2

| ETHICAL COMPLIANCE

The patient (in the St Louis case) and family (in the Ghent
case) gave written consent for publication.

3
3.1

| CASES
| St Louis

At the age of 40 years old, the proband was referred for
further evaluation in the setting of familial occurrence of
aortic aneurysms and dissection. His medical history was
notable for bilateral inguinal hernia correction. Aside from
a mild pectus excavatum and an increased arm span (ratio
1.06), he did not present any outward features reminiscent
of MFS or LDS. Echocardiography revealed an aortic root
aneurysm of 50 mm. Family history revealed a presumed
diagnosis of “Marfan syndrome” in his deceased father and
several other family members on his father’s side known
with aortic aneurysms and dissections. No one was known
to have lens dislocation. Preoperative evaluation demonstrated left ventricular dysfunction (LVEF 35%) and normal
coronary arteries. Valvular heart disease was excluded on
cardiac ultrasound. The patient underwent valve-sparing
aortic root replacement. Despite therapy with ACE inhibitors or angiotensin receptor blockers and beta blocker, he
developed progressive and severe heart failure (LVEF
15%). An implantable cardiac defibrillator (ICD) was
placed for primary prevention of sudden cardiac death.
Brief episodes of nonsustained ventricular tachycardia were
noted on subsequent ICD recordings. In the year following
diagnosis, heart failure worsened despite inotropic support,
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and a HeartMate IIâ left ventricular assist device was
inserted as a bridge to transplant. Genetic testing demonstrated a pathogenic SMAD3 variant (c.859 C>T;
p.Arg287Trp; NM_005902.3). This variant has been
reported previously by van de Laar and colleagues (van de
Laar et al., 2011) in a large family with several patients
presenting with Aneurysm Osteoarthritis syndrome. Heart
failure is not mentioned but interestingly, two family members are reported with sudden cardiac death at a young age
(35 and 39 years; Table 1).

3.2

| Ghent

The proband in this family is a young girl, presenting for
the first time at the age of 5 years after the death of her
father. Her father had been diagnosed with idiopathic dilated
cardiomyopathy at the age of 25 years. Valvular heart disease was excluded. He developed intractable heart failure at
the age of 27 and he was listed for heart transplantation. He
presented with acute aortic dissection after insertion of a
LVAD and died. Both his mother and maternal aunt had
died in their 3rd to 4th decade of life from aortic dissection.
At the age of 5 years, the proband presented some mild
Marfanoid features with joint laxity, flat feet, arachnodactylia slender build, mild myopia and mitral valve prolapse. Genetic screening of the FBN1 gene revealed the
presence of a benign polymorphism. Over the years, followup showed mild scoliosis occurring in adolescence and
stretch marks. Myopia was not progressive. She developed
retropatellar cartilage problems in both knees. She was treated throughout childhood with verapamil for symptomatic
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ventricular extrasystoles. Aortic dimensions at all levels have
always been normal. At the age of 21 years, moderate
dilatation of the left ventricle was noted on echocardiography (left ventricular end diastolic diameter 61 mm) with preserved systolic and diastolic function. Aortic root diameter
(sinus of Valsalva) was 32 mm—z-score 0.24). Holter monitoring revealed multiple ventricular couplets (5% ventricular
ectopy, 15 couplets). An electrophysiologic study did not
demonstrate any inducible arrhythmias. At the age of
22 years, she presented with an out-of-hospital cardiac
arrest. She was resuscitated by her mother and ventricular
fibrillation was documented by the EMS. Severe brain damage ensued and she died 10 days later. An autopsy excluded
aortic dissection, coronary artery anomalies or cerebral vascular abnormalities. A new genetic screening using a NGS
panel including FBN1, TGFRB1/2, ACTA2, and SMAD3
revealed a pathogenic variant in the SMAD3 gene
(c.584_585insTC; p.Gln195Hisfs*3). This variant has not
been reported elsewhere. Furthermore cascade screening in
the family revealed its presence in one man presenting severe mitral valve regurgitation due to prolapse, necessitating
valve replacement. His 40-year-old son also harbors the variant but has no cardiovascular manifestations so far.

4

| DISCUSSION

The notion of increased rates of heart failure/myocardial
dysfunction and ventricular arrhythmias/sudden cardiac
death in patients with Marfan syndrome (MFS) has been
established for several decades, both in mortality registries

T A B L E 1 Summary of clinical and genetic findings in the three reported cases
Cardiovascular features

Other clinical
manifestations

Family history

Genetic findings

Aortic Root Aneurysm (50 mm @
age 40 years)—LVEF 35% R/Valve
Sparing ARR
Postop LVEF ↓ 15%—R/LVAD
NSVT—R/ICD

Inguinal hernia
Mild Pectus
deformity
Armspan/length
ratio 1.06

Father died of “Marfan
syndrome”
Several other paternal
family members presenting
aortic aneurysm/dissection

SMAD3 c.859 C>T;
p.Arg287Trp

Father

“Idiopathic Dilated Cardiomyopathy”
@ age 25 years
Aortic dissection upon LVAD
insertion—died @ age 27 years

Long fingers

Mother and maternal
aunt aortic dissection
in 3rd decade of life

SMAD3 c.584-585inTC;
p.Gln195HisfsX3

Daughter

Mitral valve prolapse
Ventricular Extrasystole’s
LV dilatation (LVEDD 61 mm
@ 21 years)
Normal aortic root dimensions
Out of Hospital Arrest—died
@ age 22 years

Arachnodactylia
Flat feet
Joint laxity
Retropatellar
cartilage
problems

St Luis case

Ghent case

ICD, implantable cardiac defibrillator; LV, left ventricle; LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; LVAD, left ventricular assist device; NSVT, nonsustained ventricular tachycardia.
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(Gott et al., 1999; Murdoch et al., 1972) as in clinical studies (Alpendurada et al., 2010; Campens et al., 2015; Cook
et al., 2014; Hoffmann et al., 2012; Kiotsekoglou et al.,
2008, 2009; Loeper et al., 2016; Rouf et al., 2017;
Rybczynski et al., 2007; Tae et al., 2016). The exact nature
of these abnormalities is largely unknown. Suggested triggers/modifiers for myocardial dysfunction and arrhythmias
include volume overload induced by valvular regurgitation
or pressure overload by aortic arch constriction (in animals). Several studies have, however, indicated that
myocardial dysfunction may occur in the absence of any of
these triggers, suggesting an intrinsic myocardial defect
(Alpendurada et al., 2010; de Backer et al., 2006). Some
studies in animal models indicate a possible role for altered
TGFb signaling. Given the known phenotypic overlap
between MFS and other HTAD entities related to genes
encoding components of the TGFb signaling pathway,
myocardial dysfunction and arrhythmias may also be present. Limited data on patients with SMAD3 pathogenic
variants are available at present with reports of sudden cardiac death and left ventricular hypertrophy in one of the
initial series on Aneurysm Osteoarthritis Syndrome due to
SMAD3 pathogenic variants (van der Linde et al., 2012).
Here, we report the clinical summaries of three patients
harboring a pathogenic SMAD3 variant and displaying idiopathic dilated cardiomyopathy requiring advanced mechanical support in two cases and left ventricular dilatation
complicated by malignant arrhythmias in one case.
To further investigate the relevance and underlying
mechanisms of these findings, larger scale (cohort and
prospective) studies are needed. Meanwhile awareness for
the problem and appropriate investigation and management
in patients with suggestive symptoms is warranted.
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